Biopharmaceutical firm Jubilant Life Sciences has licensed molecules with potential to fight cancer to a new venture formed with Frazier Healthcare Partners.
US-based cancer therapy developer Lengo Therapeutics, which is backed by biopharmaceutical firm Jubilant Life Sciences, launched yesterday with $15m in series A funding from growth equity firm Frazier Healthcare Partners
Lengo has exclusively licensed chemicals discovered at Jubilant that could potentially combat cancerous genetic mutations unaddressed by existing cancer treatments.
The company was formed after Frazier Healthcare’s oncology team chose molecules from Jubilant’s chemical portfolio corresponding to novel mutation targets.
Jubilant and Frazier have partnered on discovery-stage collaborations since 2016.…
